


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application.

Claim 1. (original) A compound represented by Formula (I):



or a pharmaceutically acceptable salt thereof, wherein

X is phenyl, pyridinyl, thiazolyl, pyrimidinyl, pyridazinyl, furyl, thienyl, oxazolyl, isoxazolyl, isothiazolyl.

R<sup>1</sup> and R<sup>2</sup> are each independently -C<sub>1-6</sub>alkyl, -C<sub>3-6</sub>cycloalkyl, any of which optionally substituted with 1-6 independent halogen;

R<sup>3</sup> and R<sup>4</sup> are each independently -C<sub>1-6</sub>alkyl, -C<sub>3-6</sub>cycloalkyl, aryl, or heteroaryl, any of which optionally substituted with 1-6 independent halogen,

R<sup>3</sup> and R<sup>4</sup> are optionally connected by Y to form a ring, wherein Y is -C<sub>1-6</sub>alkyl-.

Claim 2. (original) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is phenyl, pyridinyl, or thiazolyl;

Claim 3. (original) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> and R<sup>4</sup> are each independently -C<sub>1-4</sub>alkyl optionally substituted with 1-6 independent halogen.

Claim 4. (original) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> and R<sup>4</sup> are optionally connected by Y to form a ring, wherein Y is -C<sub>1-4</sub>alkyl-.

Claim 5. (original) The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is phenyl.

Claim 6. (original) The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is phenyl; and R<sup>3</sup> and R<sup>4</sup> are each independently -C<sub>1-4</sub>alkyl optionally substituted with 1-6 independent halogen.


Claim 7. (original) The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is pyridinyl.

Claim 8. (original) The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is pyridinyl; and R<sup>3</sup> and R<sup>4</sup> are each independently -C<sub>1-4</sub>alkyl optionally substituted with 1-6 independent halogen.

Claim 9. (original) The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is thiazolyl.

Claim 10. (original) The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is thiazolyl; and R<sup>3</sup> and R<sup>4</sup> are each independently -C<sub>1-4</sub>alkyl optionally substituted with 1-6 independent halogen.

Claim 11. (original) The compound of claim 1, represented by



or a pharmaceutically acceptable salt thereof.

Claim 12. (original) The compound according to claim 1, consisting of  
(±)-5-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]ethyl}2-pyridone;

Chiral-5-{2-[3,4-bis(difluoromethoxy)phenyl]-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]ethyl}2-pyridone;

(±)-5-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[4-(2-hydroxypropan-2-yl)phenyl]ethyl} 2-pyridone;  
(±)-3-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]ethyl} 2-pyridone;  
(±)-5-{2-[3,4-Bis(difluoromethoxy)phenyl]-2-[2-(2-hydroxypropan-2-yl)5-pyridyl]ethyl} 2-pyridone;  
(±)-5-{2-(3-Cyclopropyloxy-4-difluoromethoxyphenyl)-2-[2-(2-hydroxypropan-2-yl)5-pyridyl]ethyl} 2-pyridone;  
Chiral-5-{2-(3-cyclopropyloxy-4-difluoromethoxyphenyl)-2-[2-(2-hydroxypropan-2-yl)5-pyridyl]ethyl} 2-pyridone;  
Chiral-5-{2-(3-cyclopropyloxy-4-difluoromethoxyphenyl)-2-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)5-thiazolyl]ethyl} 2-pyridone;  
Chiral-3-{2-(3-cyclopropyloxy-4-difluoromethoxyphenyl)-2-[2-(1-hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)5-thiazolyl]ethyl} 2-pyridone;  
or a pharmaceutically acceptable salt thereof.

Claim 13. (original) A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Claim 14. (original) The pharmaceutical composition according to claim 13, further comprising a Leukotriene receptor antagonist, a Leukotriene biosynthesis inhibitor, an M2/M3 antagonist, a corticosteroid, an H1 receptor antagonist or a beta 2 adrenoceptor agonist.

Claim 15. (original) The pharmaceutical composition according to claim 13, further comprising a COX-2 selective inhibitor, a statin, or an NSAID.

Claim 16. (original) A method of treatment or prevention of asthma; chronic bronchitis; chronic obstructive pulmonary disease; adult respiratory distress syndrome; infant respiratory distress syndrome; cough; chronic obstructive pulmonary disease in animals; adult respiratory distress syndrome; ulcerative colitis; Crohn's disease; hypersecretion of gastric acid; bacterial, fungal or viral induced sepsis or septic shock; endotoxic shock; laminitis or colic in horses; spinal cord trauma; head injury; neurogenic inflammation; pain; reperfusion injury of the

brain; psoriatic arthritis; rheumatoid arthritis; ankylosing spondylitis; osteoarthritis; inflammation; or cytokine-mediated chronic tissue degeneration comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

Claim 17. (original) A method of treatment or prevention of allergic rhinitis, allergic conjunctivitis, eosinophilic granuloma, osteoporosis, arterial restenosis, atherosclerosis, reperfusion injury of the myocardium chronic glomerulonephritis, vernal conjunctivitis, cachexia, transplant rejection, or graft versus host disease, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

Claim 18. (original) A method of treatment or prevention of depression, memory impairment, monopolar depression, Parkinson disease, Alzheimer's disease, acute and chronic multiple sclerosis, psoriasis, benign or malignant proliferative skin diseases, atopic dermatitis, urticaria, cancer, tumor growth or cancerous invasion of normal tissues, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

Claim 19-21 (cancelled)